Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in moderately to severely active systemic lupus erythematosus
NCT06456567Phase 3Withdrawn
- Sponsor
- Vor Bio
- Start
- Sep 2024
- Primary completion
- Jan 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of telitacicept in systemic lupus erythematosus (SLE), sponsored by Vor Bio. Planned start Sep 2024; status: withdrawn.
02
Drugs
telitacicept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06456567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06456567.